About: Effect of COVID-19 on patients with compensated chronic liver diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of COVID-19 on patients with compensated chronic liver diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effect of COVID-19 on patients with compensated chronic liver diseases
Creator	Chen, Zhu Li, Chen Xu, Jing Zhang, Dawei Cheng, Gregory Ji, Dong Qin, Enqiang Wang, Yudong Lau, · Mu, Jinsong Zhao, · Yang, Tieniu
source	Medline; PMC
abstract	BACKGROUND AND AIM: Cytokine storm has been reported in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We examine the incidence of acute on chronic liver failure (ACLF) in COVID-19 patients with pre-existing compensated chronic liver disease (CLD). METHODS: From 20 Jan 2020 to 7 Feb 2020, we studied 140 consecutive COVID-19 patients admitted to either Fuyang Second People’s Hospital (FYSPH), Anhui or the Fifth Medical Center of Chinese PLA General Hospital (PLAGH) in Beijing, China. Pre-existing CLD includes those with liver cirrhosis assessed by APRI/FIB-4 score and /or ultrasound; NAFLD as identified by either ultrasound or hepatic steatosis index with significant liver fibrosis and chronic hepatitis B (CHB) or hepatitis C (CHC) infection. The diagnosis, grading of severity and clinical management of COVID-19 patients complied to the guideline and clinical protocol issued by the China National Health Commission. All patients had liver function test at least twice weekly till discharge with full recovery or death. RESULTS: In total, 3 had liver cirrhosis, 6 patients had CHB, 13 had NAFLD with significant liver fibrosis (one also had CHB). On admission, none had liver decompensation. COVID-19 disease progression was significantly less frequent in non-CLD patients (10/118 8.5%) than CLD patients (13/22 59.1%, p < 0.001). One patient with CLD had acute-on-chronic liver failure (ACLF). CONCLUSION: Disease progression is significantly higher in those COVID-19 patients with CLD as compared to those with no CLD. ACLF can also occur in patient with pre-existing compensated CLD who had severe COVID-19.
has issue date	2020-07-30(xsd:dateTime)
bibo:doi	10.1007/s12072-020-10058-6
bibo:pmid	32734407
has license	no-cc
sha1sum (hex)	985af9ff48515f71f942216540e01d635e0f2a8b
schema:url	https://doi.org/10.1007/s12072-020-10058-6
resource representing a document's title	Effect of COVID-19 on patients with compensated chronic liver diseases
has PubMed Central identifier	PMC7391917
has PubMed identifier	32734407
schema:publication	Hepatol Int
resource representing a document's body	covid:985af9ff48515f71f942216540e01d635e0f2a8b#body_text
is schema:about of	named entity 'COVID-19' named entity 'liver tissue' named entity 'ACLF' named entity 'COVID' named entity 'bile duct' named entity 'fibrosis' named entity 'Fisher's exact test' named entity 'transaminases' named entity 'clinical characteristics' named entity 'reverse-transcriptase' named entity 'COVID' named entity 'nasal swab' named entity 'NUCs' named entity 'TNF-alpha' named entity 'total bilirubin' named entity 'follow-up' named entity 'hypoxia' named entity 'post-mortem' named entity 'AST' named entity 'intensive care unit' named entity 'Chronic liver disease' named entity 'liver' named entity 'COVID' named entity 'COVID' named entity '11.3' named entity 'serum ferritin' named entity 'TBIL' named entity 'Chest X-ray' named entity 'entecavir' named entity 'HBV' named entity 'IL-6' named entity 'coagulopathy' named entity 'immune mediated' named entity 'coagulopathy' named entity 'SARS-CoV-2' named entity 'CD8 +' named entity 'life support' named entity 'biopsies' named entity 'Oxygen therapy' named entity 'acute decompensation' named entity 'ACE2' named entity 'systemic inflammation' named entity 'liver injury' named entity 'ACLF' named entity 'abdominal ultrasound' named entity 'hypoxic' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'liver' named entity 'CHB' named entity 'lopinavir' named entity 'COVID-19' named entity 'type 2 diabetes' named entity 'HBV' named entity 'medical records' named entity 'aspartate transaminase' named entity 'liver injury' named entity 'liver damage' named entity 'lobular' named entity 'autopsy' named entity 'CLD' named entity 'chronic liver disease' named entity 'R Foundation' named entity 'cirrhosis' named entity 'chi-square test' named entity 'lymphocytic infiltration' named entity 'polymerase chain reaction' named entity 'continuous renal replacement therapy' named entity 'organ' named entity 'symptom'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software